Copper Compound Clears 42 Percent of Alzheimer's Toxic Proteins in Mice

Elementary

Researchers at Monash University in Melbourne, Australia, have published a study about a copper compound that helps mice with Alzheimer's disease. The study appeared in the scientific journal ACS Chemical Neuroscience in June 2026.

The compound is called Cu(ATSM). Scientists gave it to mice for 56 days. At the end of the study, the mice had 42 percent fewer harmful protein clumps in their brains. These clumps are called amyloid-beta plaques.

The treated mice also improved at spatial learning tests. Spatial learning means understanding where things are in space, for example navigating a water maze. Treated mice improved by 44 percent compared to untreated mice.

Scientists think Cu(ATSM) works by fixing a protein pump in the brain. This pump normally removes amyloid-beta from the brain. In Alzheimer's disease the pump works poorly. Cu(ATSM) appears to restore it, helping to clear the harmful plaques.

compound: a substance made from two or more chemical elements joined together

plaque: a harmful build-up of protein that collects in the brain in Alzheimer's disease

amyloid-beta: a protein fragment that clumps together and damages brain cells in Alzheimer's disease

spatial learning: the ability to understand and remember the layout of an environment

journal: a scientific magazine where researchers publish their findings

restore: to bring something back to its original good condition

navigate: to find one's way through an area or environment

pump: a device or protein that moves a substance from one place to another

Intermediate

A team at Monash University, Melbourne, has reported promising results using the copper compound Cu(ATSM) in a mouse model of Alzheimer's disease. Published in ACS Chemical Neuroscience in June 2026, the study documents a 42 percent reduction in cortical amyloid-beta plaques and a 44 percent improvement in spatial memory over a 56-day oral dosing regimen.

The key mechanism centres on the blood-brain barrier (BBB), a selective membrane that controls what enters the brain. A transporter protein called P-glycoprotein (P-gp) normally pumps amyloid-beta out of the brain. In Alzheimer's disease, P-gp levels fall by 30 to 40 percent. The study found that Cu(ATSM) raised P-gp levels by 24.1 percent, helping to clear amyloid-beta more effectively.

Cu(ATSM) also appears to boost microglial phagocytosis. Microglia are the brain's resident immune cells, and phagocytosis is the process by which they engulf and destroy harmful material. Together with restored P-gp activity, this dual mechanism may explain the significant reduction in plaques observed in treated mice.

The compound offers practical clinical advantages. It is orally bioavailable, meaning it can be taken as a pill, and it crosses the blood-brain barrier naturally. It has already passed Phase 1 human safety trials for Parkinson's disease and ALS. However, the study used the 5xFAD mouse model, which overexpresses five aggressive familial mutations and may not fully represent sporadic late-onset Alzheimer's, the form that accounts for over 95 percent of human cases.

blood-brain barrier: a selective membrane of cells that controls the passage of substances from the bloodstream into the brain

P-glycoprotein (P-gp): a transporter protein at the blood-brain barrier that pumps harmful substances such as amyloid-beta out of the brain

microglial phagocytosis: the process by which microglia, the brain's immune cells, engulf and destroy harmful material

oral bioavailability: the proportion of a drug that reaches the bloodstream when taken by mouth

familial mutation: a genetic change that runs in families and causes an inherited form of a disease

sporadic: occurring irregularly without a clear inherited genetic cause

transporter protein: a protein that moves specific molecules across a cell membrane

ALS: amyotrophic lateral sclerosis, a progressive disease that attacks motor nerve cells in the brain and spinal cord

Advanced

Researchers at Monash University have demonstrated a dual-mechanism approach to amyloid clearance using Cu(ATSM), copper diacetyl bis(4-methylthiosemicarbazone), in the 5xFAD transgenic mouse model. Published in ACS Chemical Neuroscience in June 2026, the study documents a 42 percent reduction in cortical amyloid-beta plaque burden and a 44 percent improvement in Morris water maze performance over a 56-day oral dosing regimen.

The primary mechanism centres on P-glycoprotein (P-gp), an ATP-binding cassette (ABC) efflux transporter expressed at the luminal surface of blood-brain barrier endothelial cells. P-gp mediates vectorial export of amyloid-beta from brain parenchyma to blood. In Alzheimer's disease, P-gp expression declines 30 to 40 percent, impairing amyloid efflux. Cu(ATSM) treatment rescued P-gp expression by 24.1 percent relative to untreated transgenic controls, with corresponding restoration of efflux transport capacity.

A secondary mechanism involves microglial priming. Cu(ATSM) potentiated microglial phagocytic uptake of amyloid-beta in vitro, suggesting that brain-resident macrophages contribute to plaque clearance alongside restored barrier efflux. The compound's pharmacokinetic profile supports clinical translation: oral bioavailability is established, CNS penetrance has been confirmed, and Cu(ATSM) has completed Phase 1 safety trials in both Parkinson's disease and ALS with no significant adverse events reported.

Significant translational caveats apply. The 5xFAD model overexpresses five familial Alzheimer's mutations (APP Swedish, Florida, London; PSEN1 M146L, L286V), generating aggressive early-onset amyloidosis that diverges substantially from sporadic late-onset Alzheimer's disease, which represents approximately 95 percent of the human disease burden. Amyloid clearance has historically not translated linearly from mouse to human, as the immunotherapy failures of bapineuzumab and solanezumab in late-stage trials underscore. Nonetheless, Cu(ATSM)'s existing human safety data, oral route of administration, and mechanistically distinct P-gp restoration strategy warrant a controlled Phase 2 trial targeting early or preclinical sporadic Alzheimer's disease.

ABC efflux transporter: a membrane protein belonging to the ATP-binding cassette family that uses energy from ATP hydrolysis to pump substrates out of a cell

luminal surface: the inner-facing surface of a hollow structure, here the blood-vessel side of the blood-brain barrier endothelium

parenchyma: the functional tissue of an organ, as opposed to its connective or supporting framework

vectorial transport: directional movement of a molecule across a membrane from one compartment to another

microglial priming: a state of heightened readiness in microglia that amplifies their phagocytic and inflammatory responses to subsequent stimuli

pharmacokinetic profile: the description of how a drug is absorbed, distributed, metabolised, and excreted within the body over time

amyloidosis: a condition characterised by abnormal deposits of amyloid protein in tissues, damaging their function

bapineuzumab / solanezumab: monoclonal antibodies targeting amyloid-beta that failed to improve clinical outcomes in Phase 3 Alzheimer's trials, illustrating the translational gap between mouse models and human disease

Absolute Beginner

Elementary

Intermediate

Advanced

Copper Compound Clears 42 Percent of Alzheimer's Toxic Proteins in Mice

Multiple Choice

True or False

Fill in the Blank